Great to finally get an update on progress with NNZ-2591 and theses are excellent results, albeit in a mouse model.
But I can’t help but ask, “What the hell is going on?”
I note that the SHANK3 knockout mouse model study for NNZ-2591 in Phelan McDermid Syndrome (PMS) was performed by the London-based CRO, GeN.DDi Limited. Patricia Cogram is the Founder and CEO of this company. Dr Cogram has previously conducted the knockout mouse models for both trofinetide and NNZ-2591 in Fragile-x and is listed as an inventor on the NNZ-2591 patents.
In 2017 Dr Cogram co-authored a paper, AM0-1 in the Shank3 knockout Transgenic Mouse Model of Phelan McDermid Syndrome, with AMO CEO, Dr Michael Snape and AMO CEO and CMO, Dr Joe Horrigan. AMO-1 performed well in this preclinical trial and progressed to Phase 1 and Phase 2 studies. The current 10 patient Phase 2 study of AMO-1 in PMS is due to complete next month.
AMO-1 has already been mentioned on this forum, but with respect to its development in Fragile-x. Two years ago, AMO listed Fragile-x as its lead program for AMO-1 on its website, but now its PMS.
A second drug, AMO-2 has also been previously mentioned on this forum. Last year, Phase 2 results of AMO-2 in ASD were released. However, the AMO website now lists Congenital myotonic dystrophy as the lead program for AMO-2.
There is AMO-4 (tianeptine) in AMO’s pipeline. Tianeptine is a repurposed drug which has already been approved for other indications such as depression, Parkinson’s disease, post-traumatic brain disorder, and asthma. AMO Pharma entered into a development and license agreement with Numedicus Limited to advance the development of AMO-4 for the treatment of Rett syndrome and certain breathing disorders. Though the AMO website shows AMO-4 in Phase 2, it’s unclear where progress is at with the Rett program. It was reported last year that tianeptine had been reviewed in Europe and would commence trials there this year.
That's an extraordinary amount of overlap.
Great to finally get an update on progress with NNZ-2591 and...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.96 |
Change
-2.150(9.30%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $22.50 | $22.70 | $20.28 | $24.29M | 1.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 259 | $20.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.98 | 1641 | 2 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.07 |
Change
-2.150 ( 9.39 %) |
||||
| Open | High | Low | Volume | ||
| $22.45 | $22.67 | $20.27 | 399615 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| NEU (ASX) Chart |